The trial in 10 countries in Latin America and Europe will continue, and a final result is not expected until the end of June. The CureVac vaccine is of key importance to Europe, which has preordered 225 million doses.
CureVac, the latest experimental coronavirus vaccine, proved just 47 percent effective amid spread of variants, preliminary analysis shows
